CN105705645B - 逆转录病毒载体 - Google Patents

逆转录病毒载体 Download PDF

Info

Publication number
CN105705645B
CN105705645B CN201480057140.0A CN201480057140A CN105705645B CN 105705645 B CN105705645 B CN 105705645B CN 201480057140 A CN201480057140 A CN 201480057140A CN 105705645 B CN105705645 B CN 105705645B
Authority
CN
China
Prior art keywords
carrier
vector
sequence
rna
long terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480057140.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105705645A (zh
Inventor
康纳德·温克
斯蒂文·霍维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ucl Commercial Co Ltd
Original Assignee
Ucl Commercial Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Commercial Co Ltd filed Critical Ucl Commercial Co Ltd
Publication of CN105705645A publication Critical patent/CN105705645A/zh
Application granted granted Critical
Publication of CN105705645B publication Critical patent/CN105705645B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480057140.0A 2013-10-16 2014-10-16 逆转录病毒载体 Active CN105705645B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1318347.0 2013-10-16
GBGB1318347.0A GB201318347D0 (en) 2013-10-16 2013-10-16 Retroviral vectors
PCT/GB2014/053102 WO2015056014A1 (en) 2013-10-16 2014-10-16 Retroviral vectors

Publications (2)

Publication Number Publication Date
CN105705645A CN105705645A (zh) 2016-06-22
CN105705645B true CN105705645B (zh) 2019-11-15

Family

ID=49680159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480057140.0A Active CN105705645B (zh) 2013-10-16 2014-10-16 逆转录病毒载体

Country Status (7)

Country Link
US (1) US10184136B2 (enExample)
EP (1) EP3058076B1 (enExample)
JP (1) JP6525986B2 (enExample)
CN (1) CN105705645B (enExample)
ES (1) ES2759049T3 (enExample)
GB (1) GB201318347D0 (enExample)
WO (1) WO2015056014A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
KR102673203B1 (ko) * 2016-04-20 2024-06-10 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. Pklr의 유전자 발현 증강을 위한 조성물 및 방법
AU2017322511B2 (en) * 2016-09-08 2021-08-26 Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. Gene therapy for patients with Fanconi anemia
JP7290288B2 (ja) * 2017-08-22 2023-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でｆｏｘｐ３を発現するレンチウイルスベクター
CN119345398A (zh) 2017-10-16 2025-01-24 能源环境和技术研究中心O.A.,M.P. 用于递送pklr以治疗丙酮酸激酶缺乏症的慢病毒载体
AU2019261646A1 (en) 2018-04-27 2020-11-12 Spacecraft Seven, Llc Gene therapy for CNS degeneration
CN108676815A (zh) * 2018-05-31 2018-10-19 深圳市免疫基因治疗研究院 一种b型血友病慢病毒载体、慢病毒及其制备方法和应用
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN113966397A (zh) 2019-03-08 2022-01-21 黑曜石疗法公司 人碳酸酐酶2组合物和用于可调调节的方法
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
AU2021320902A1 (en) 2020-08-07 2023-04-06 Spacecraft Seven, Llc Plakophilin-2 (PKP2) gene therapy using AAV vector
GB202019084D0 (en) * 2020-12-03 2021-01-20 Ucl Business Ltd Retroviral vectors
JP2024504422A (ja) * 2021-01-25 2024-01-31 プリベイル セラピューティクス，インコーポレーテッド Ａａｖに基づく遺伝子発現の調節
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
EP4473097A1 (en) 2022-02-02 2024-12-11 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
CN114931652B (zh) * 2022-06-23 2024-01-26 中国人民解放军陆军军医大学第一附属医院 一种Hmga2基因在修复受损视网膜中的应用
CA3259982A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics, Inc. COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
GB202306491D0 (en) 2023-05-03 2023-06-14 Ucl Business Ltd Retroviral vectors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714353A (en) * 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
CN101291688A (zh) * 2005-10-17 2008-10-22 巴斯德研究所 基于慢病毒载体的疫苗
CN102443604A (zh) * 2011-11-25 2012-05-09 上海市儿童医院 一种安全性慢病毒载体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707091B1 (fr) * 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
FR2751345B1 (fr) 1996-07-16 1998-09-18 Univ Paris Curie Lignees d'encapsidation hautement productrices
US20050266544A1 (en) 1999-04-30 2005-12-01 Human Gene Therapy Research Institute Methods and compositions for increasing viral vector production in packaging cell lines
US20070048285A1 (en) * 2005-08-24 2007-03-01 Christopher Baum Self-inactivating retroviral vector

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714353A (en) * 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
CN101291688A (zh) * 2005-10-17 2008-10-22 巴斯德研究所 基于慢病毒载体的疫苗
CN102443604A (zh) * 2011-11-25 2012-05-09 上海市儿童医院 一种安全性慢病毒载体及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A self-deletion lentiviral vector to reduce the risk of replication-competent virus formation;Fang Y等;《The Journal of Gene Medicine》;20130214;第15卷(第2期);参见全文 *
Fang Y等.A self-deletion lentiviral vector to reduce the risk of replication-competent virus formation.《The Journal of Gene Medicine》.2013,第15卷(第2期), *
LTR1: A Novel Lentiviral Vector Designed;Conard AV等;《Applications of Genome Editing & Gene Targeting》;20140531;第22卷;参见摘要 *

Also Published As

Publication number Publication date
US20160230191A1 (en) 2016-08-11
WO2015056014A1 (en) 2015-04-23
EP3058076B1 (en) 2019-09-18
CN105705645A (zh) 2016-06-22
JP2016539629A (ja) 2016-12-22
EP3058076A1 (en) 2016-08-24
JP6525986B2 (ja) 2019-06-05
GB201318347D0 (en) 2013-11-27
US10184136B2 (en) 2019-01-22
ES2759049T3 (es) 2020-05-07

Similar Documents

Publication Publication Date Title
CN105705645B (zh) 逆转录病毒载体
JP6001702B2 (ja) ポリプリントラクト改変レトロウイルスベクター
CN1195864C (zh) 慢病毒载体
ES2959326T3 (es) Líneas celulares estables para producción retroviral
ES2951857T3 (es) Vector retroviral
US20060177934A1 (en) Lentiviral LTR-deleted vector
KR20010033064A (ko) 높은 역가를 갖는 안전한 재조합 렌티바이러스 벡터를생성시키는 방법 및 수단
JP2023516493A (ja) レンチウイルスベクター
JP2023513303A (ja) レンチウイルスベクターの製造
US20180127470A1 (en) Cell Lines
JP2025129152A (ja) 産生系
ES2744448T5 (es) Vectores para la expresión transgénica
Santhosh et al. A lentiviral vector with novel multiple cloning sites: stable transgene expression in vitro and in vivo
CN101302537B (zh) 一种位点特异整合性慢病毒载体系统及其制备方法
US7220578B2 (en) Single LTR lentivirus vector
US9840720B2 (en) Materials and methods relating to packaging cell lines
Pandya et al. Lentivirus and foamy virus vectors: novel gene therapy tools
US20230416777A1 (en) Moloney murine leukemia virus-based self-inactivating vector and applications thereof
Barker et al. Vectors derived from the human immunodeficiency virus, HIV-1
Spirin et al. Lentiviral vectors
NZ522264A (en) Retroviral vectors comprising an enhanced 3' transcription termination structure
KR20240024807A (ko) 렌티바이러스 벡터
van Heuvel Optimization of retroviral packaging cells for scale-up of vector production
Binder et al. Lentivirus vectors
WO2021204655A1 (en) Modified vectors for production of retrovirus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant